Cytosurge AG, Glattbrugg, Switzerland, has announced a spin-off of its Additive Manufacturing business unit, stating that the new company will focus on providing solutions for processes and instruments in the field of microscopically small metal components. The new independent entity will operate under the name Exaddon AG, and will be led by Edgar Hepp who takes the role of CEO.
According to Cytosurge, the establishment of the spin-off company was initiated by exploring the applicability of its proprietary FluidFM® technology to the field of additive micro-manufacturing. Originally developed at ETH Zurich a decade ago, FluidFM has already resulted in several highly innovative solutions for customers in the pharmaceutical industry, as well as academic research in the field of cell- and bioscience.
Dr Pascal Behr, CEO of Cytosurge, stated, “Given the unique nature of the Additive Manufacturing business and specific requirements of our key target markets such as the semiconductor industry, we are convinced that an independent company can realise the high growth opportunities in this emerging market much better if it can focus entirely on this key goal. We are very proud to announce today the establishment of Exaddon AG for this purpose and I am convinced that Edgar and his team will thrive.”
“We have developed a ground-breaking manufacturing technology and have brought it to market maturity. It enables our clients to additively manufacture high-end products at an unprecedented level,” commented Hepp. “Exaddon AG is now responsible for all Cytosurge AG projects related to Additive Manufacturing and will continue to manage and develop them.”
Cytosurge states that the companies will continue to collaborate closely and cooperate on selected strategic projects.